NEJM: Latest Research & Medical Advances

The management of critically ill adults often requires tracheal intubation – the placement of a tube into the airway to assist breathing. A central question for clinicians is which medication to employ to facilitate this process. Recent research, highlighted in the New England Journal of Medicine, is revisiting the comparison between ketamine and etomidate for this purpose, specifically focusing on potential impacts on blood pressure and other vital signs.

Understanding the Medications

Both ketamine and etomidate are intravenous anesthetic agents used to induce unconsciousness quickly, which is essential during rapid sequence intubation (RSI) in emergency situations. RSI is a procedure used to intubate patients quickly and safely, minimizing the risk of aspiration (inhaling stomach contents into the lungs). However, they have different pharmacological profiles and potential side effects.

Etomidate has traditionally been favored for its hemodynamic stability – meaning it tends to have less impact on blood pressure. However, concerns have been raised about its potential to suppress adrenal function, which could be problematic in patients already under significant stress.

Ketamine, is known for its bronchodilatory effects (opening up the airways) and its ability to maintain or even increase blood pressure. This can be particularly beneficial in patients who are hypotensive (have low blood pressure) or at risk of developing hypotension. However, ketamine has been associated with increased intracranial pressure and potential psychological side effects, such as emergence delirium.

Recent Findings and the Ongoing Debate

The research published in the New England Journal of Medicine, specifically a correspondence published February 26, 2026, focuses on cerebral folate deficiency, autism, and the role of leucovorin. Whereas not directly addressing ketamine versus etomidate, it underscores the journal’s commitment to rigorously vetting and compiling the latest medical research. The broader context of emergency medicine is constantly evaluating the best practices for intubation, and the choice between these drugs remains a topic of active discussion.

Historically, etomidate was often the preferred agent due to its perceived hemodynamic stability. However, growing evidence suggests that ketamine’s impact on blood pressure may not be as detrimental as previously thought, particularly when used in carefully selected patients. The adrenal suppression concerns with etomidate have led some clinicians to reconsider its routine use.

Who is Affected by This Discussion?

This debate directly affects critically ill adults requiring tracheal intubation in a variety of settings, including emergency departments, intensive care units, and operating rooms. Patients with conditions such as sepsis, trauma, respiratory failure, and cardiac arrest are among those who may require this procedure. The choice of induction agent can influence their physiological response during intubation and potentially impact their overall outcome.

Evidence and Limitations

The optimal choice between ketamine and etomidate is not definitively established. Much of the evidence comes from observational studies and retrospective analyses, which are prone to biases and confounding factors. Randomized controlled trials (RCTs) – considered the gold standard of medical research – are challenging to conduct in this population due to the urgency of the situation and the heterogeneity of patients.

A key limitation of many studies is the difficulty in isolating the effect of the induction agent from other factors that influence blood pressure and hemodynamic stability, such as the patient’s underlying medical conditions, volume status, and concurrent medications. The dosage of the drugs used can vary significantly, making it difficult to compare results across studies.

What Does This Mean in Plain English?

The choice between ketamine and etomidate for tracheal intubation is not a simple one. There isn’t a single “best” drug for all patients. Clinicians must carefully weigh the potential benefits and risks of each agent, taking into account the individual patient’s clinical condition and hemodynamic status.

For patients with low blood pressure or at risk of developing hypotension, ketamine may be a reasonable choice. For patients with concerns about adrenal function, etomidate might be considered, whereas the potential risks should be carefully evaluated. The decision should be made on a case-by-case basis, guided by the best available evidence and clinical judgment.

Risk Context: Balancing Benefits and Potential Harms

It’s essential to remember that both ketamine and etomidate carry potential risks. While etomidate is associated with adrenal suppression, the clinical significance of this effect is still debated. Ketamine, while generally well-tolerated, can cause emergence delirium and may increase intracranial pressure in certain patients. The absolute risk of these adverse events is relatively low, but clinicians must be aware of them and take appropriate precautions.

The Public Health Process: How Guidance Evolves

Medical practice is constantly evolving as new evidence emerges. Guidelines for tracheal intubation are regularly reviewed and updated by professional organizations such as the American Society of Anesthesiologists (ASA) and the Society of Critical Care Medicine (SCCM). These organizations analyze the available evidence and develop recommendations for best practice. The NEJM Group plays a vital role in disseminating this research to clinicians worldwide.

What Comes Next: Ongoing Research and Surveillance

Further research is needed to definitively determine the optimal induction agent for tracheal intubation in critically ill adults. Ongoing clinical trials are investigating the effects of different dosages and combinations of drugs. Surveillance systems are monitoring the incidence of adverse events associated with both ketamine and etomidate to identify potential safety signals. Clinicians are encouraged to participate in these efforts and to report any unexpected or concerning outcomes.

The field is similarly exploring alternative induction agents and techniques, such as the use of dexmedetomidine, a sedative with minimal impact on blood pressure. The goal is to provide the safest and most effective care for patients requiring tracheal intubation.